Literature DB >> 25124078

Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.

K W Crawford1, S Wakabi, F Magala, H Kibuuka, M Liu, T E Hamm.   

Abstract

OBJECTIVES: Viral load (VL) monitoring is recommended, but seldom performed, in resource-constrained countries. RV288 is a US President's Emergency Plan for AIDS Relief (PEPFAR) basic programme evaluation to determine the proportion of patients on treatment who are virologically suppressed and to identify predictors of virological suppression and recovery of CD4 cell count. Analyses from Uganda are presented here.
METHODS: In this cross-sectional, observational study, patients on first-line antiretroviral therapy (ART) (efavirenz or nevirapine+zidovudine/lamivudine) from Kayunga District Hospital and Kagulamira Health Center were randomly selected for a study visit that included determination of viral load (HIV-1 RNA), CD4 cell count and clinical chemistry tests. Subjects were recruited by time on treatment: 6-12, 13-24 or >24 months. Logistic regression modelling identified predictors of virological suppression. Linear regression modelling identified predictors of CD4 cell count recovery on ART.
RESULTS: We found that 85.2% of 325 subjects were virologically suppressed (viral load<47 HIV-1 RNA copies/ml). There was no difference in the proportion of virologically suppressed subjects by time on treatment, yet CD4 counts were higher in each successive stratum. Women had higher median CD4 counts than men overall (406 vs. 294 cells/μL, respectively; P<0.0001) and in each time-on-treatment stratum. In a multivariate logistic regression model, predictors of virological suppression included efavirenz use [odds ratio (OR) 0.47; 95% confidence interval (CI) 0.22-1.02; P=0.057], lower cost of clinic visits (OR 0.815; 95% CI 0.66-1.00; P=0.05), improvement in CD4 percentage (OR 1.06; 95% CI 1.014-1.107; P=0.009), and care at Kayunga vs. Kangulamira (OR 0.47; 95% CI 0.23-0.92; P=0.035). In a multivariate linear regression model of covariates associated with CD4 count recovery, time on highly active antiretroviral therapy (ART) (P<0.0001), patient satisfaction with care (P=0.038), improvements in total lymphocyte count (P<0.0001) and haemoglobin concentration (P=0.05) were positively associated, whereas age at start of ART (P=0.0045) was negatively associated with this outcome.
CONCLUSIONS: High virological suppression rates are achievable on first-line ART in Uganda. The odds of virological suppression were positively associated with efavirenz use and improvements in CD4 cell percentage and total lymphocyte count and negatively associated with the cost of travel to the clinic. CD4 cell reconstitution was positively associated with CD4 count at study visit, time on ART, satisfaction with care at clinic, haemoglobin concentration and total lymphocyte count and negatively associated with age.
© 2014 British HIV Association.

Entities:  

Keywords:  US President's Emergency Plan for AIDS Relief (PEPFAR); Uganda; first-line regimen; sub-Saharan Africa; treatment outcomes; virological suppression

Mesh:

Substances:

Year:  2014        PMID: 25124078     DOI: 10.1111/hiv.12177

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  15 in total

1.  A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database Cohort.

Authors: 
Journal:  AIDS Res Hum Retroviruses       Date:  2016-05-03       Impact factor: 2.205

2.  HIV viral suppression and geospatial patterns of HIV antiretroviral therapy treatment facility use in Rakai, Uganda.

Authors:  Veena G Billioux; Mary K Grabowski; Joseph Ssekasanvu; Steven J Reynolds; Amanda Berman; Jeremiah Bazaale; Eshan U Patel; Eva Bugos; Anthony Ndyanabo; Alice Kisakye; Joseph Kagaayi; Ronald H Gray; Gertrude Nakigozi; Robert Ssekubugu; Fred Nalugoda; David Serwadda; Maria J Wawer; Larry W Chang
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

3.  Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD.

Authors:  Awachana Jiamsakul; Stephen J Kerr; Oon Tek Ng; Man Po Lee; Romanee Chaiwarith; Evy Yunihastuti; Kinh Van Nguyen; Thuy Thanh Pham; Sasisopin Kiertiburanakul; Rossana Ditangco; Vonthanak Saphonn; Benedict L H Sim; Tuti Parwati Merati; Wingwai Wong; Pacharee Kantipong; Fujie Zhang; Jun Yong Choi; Sanjay Pujari; Adeeba Kamarulzaman; Shinichi Oka; Mahiran Mustafa; Winai Ratanasuwan; Boondarika Petersen; Matthew Law; Nagalingeswaran Kumarasamy
Journal:  Trop Med Int Health       Date:  2016-03-29       Impact factor: 2.622

4.  Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern Ethiopia.

Authors:  Kesetebirhan Delele Yirdaw; Susan Hattingh
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

5.  The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.

Authors:  Lin He; Xiaohong Pan; Zhihui Dou; Peng Huang; Xin Zhou; Zhihang Peng; Jinlei Zheng; Jiafeng Zhang; Jiezhe Yang; Yun Xu; Jun Jiang; Lin Chen; Jianmin Jiang; Ning Wang
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

6.  Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.

Authors:  Jemma O'Connor; Colette Smith; Fiona C Lampe; Margaret A Johnson; David R Chadwick; Mark Nelson; David Dunn; Alan Winston; Frank A Post; Caroline Sabin; Andrew N Phillips
Journal:  Lancet HIV       Date:  2017-05-04       Impact factor: 12.767

Review 7.  Systematic review of statistically-derived models of immunological response in HIV-infected adults on antiretroviral therapy in Sub-Saharan Africa.

Authors:  Joseph B Sempa; Eva L Ujeneza; Martin Nieuwoudt
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

8.  Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.

Authors:  Doris Mutabazi Mwesigire; Albert W Wu; Faith Martin; Achilles Katamba; Janet Seeley
Journal:  BMC Health Serv Res       Date:  2015-07-28       Impact factor: 2.655

9.  Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.

Authors:  Vivek Jain; Wei Chang; Dathan M Byonanebye; Asiphas Owaraganise; Ellon Twinomuhwezi; Gideon Amanyire; Douglas Black; Elliot Marseille; Moses R Kamya; Diane V Havlir; James G Kahn
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

10.  First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.

Authors:  Barbara Castelnuovo; Agnes Kiragga; Frank Mubiru; Andrew Kambugu; Moses Kamya; Steven J Reynolds
Journal:  J Int AIDS Soc       Date:  2016-06-17       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.